BMS,IMS,EMAS,RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

EMA Pharmacovigilance Risk Assessment Committee PRAC recommendations on signals Adopted at the 11-14 May 2020 PRAC meeting, https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-11-14-may-2020-prac-meeting_en.pdf (accessed 16 December 2020).

National Institute for Health and Care Excellence. Menopause: diagnosis and management. London, UK: NICE, 2015.

Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159–1168.

Chlebowski RT Anderson GL Aragaki AK , et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 2020; 324: 369–380.

Rossouw JE Anderson GL Prentice RL , et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.

de Villiers TJ Hall JE, J. V. Pinkerton JV , et al. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016; 91: 153–155.

Baber RJ Panay N , and the IMS Writing Group. IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19: 109–150.

Marsden J, Pedder H and Santen R. British Menopause Society with acknowledgement to Professor Richard Santen. Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. Post Reprod Health. Epub ahead of print 23 July 2020. DOI: 10.1177/2053369120934026

Hamoda H, Panay N, Pedder H, et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health 2020; 26(4): 181–209.

The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2018; 25: 1362–1387.

Fournier A Mesrine S Dossus L , et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat2014; 145: 535–543.

Fournier A Berrino F and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–111.

Avis NE Carolina N Crawford SL. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA 2015; 175: 531–539.

The British Menopause Society, https://thebms.org.uk/wp content/uploads/2016/04/BMSNationalSurvey-MARCH2017.pdf (accessed 16 December 2020).

Boardman HM Hartley L Eisinga A , et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev 2015; 3: CD002229.

Manson JE Aragaki AK Rossouw JE , etal. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA 2017; 318: 927–938.

Manson JE Aragaki AK Bassuk SS , et al. Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. Ann Intern Med 2019; 171: 406–414.

Mikkola TS Tuomikoski P Lyytinen H , et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015; 22: 976–983.

Salpeter SR Cheng J Thabane L , et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009; 122: 1016–1022.e1.

Beral V Reeves G Bull D Green J ; Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011; 103: 296–305.

Zhu L Jiang X Sun Y , et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 2016; 23: 461–470.